Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP323.

NCT00484536 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00484536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00484536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP323.
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2007
Completion date
July 31, 2010
Enrollment
232 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis